🎉 M&A multiples are live!
Check it out!

Genmab Valuation Multiples

Discover revenue and EBITDA valuation multiples for Genmab and similar public comparables like Vivoryon Therapeutics, Pharming, and Benevolent AI.

Genmab Overview

About Genmab

Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab’s proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab’s leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.


Founded

1998

HQ

Denmark
Employees

2.7K+

Website

genmab.com

Financials

LTM Revenue $22.3B

LTM EBITDA $7.8B

EV

$9.7B

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 12K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Genmab Financials

Genmab has a last 12-month revenue (LTM) of $22.3B and a last 12-month EBITDA of $7.8B.

In the most recent fiscal year, Genmab achieved revenue of $452M and an EBITDA of $204M.

Genmab expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Genmab valuation multiples based on analyst estimates

Genmab P&L

LTM NTM Last FY FY 2025 FY 2026 FY 2027
Revenue $22.3B XXX $452M XXX XXX XXX
Gross Profit $21.2B XXX $432M XXX XXX XXX
Gross Margin 95% XXX 95% XXX XXX XXX
EBITDA $7.8B XXX $204M XXX XXX XXX
EBITDA Margin 35% XXX 45% XXX XXX XXX
EBIT $7.1B XXX $147M XXX XXX XXX
EBIT Margin 32% XXX 33% XXX XXX XXX
Net Profit $7.3B XXX $165M XXX XXX XXX
Net Margin 33% XXX 36% XXX XXX XXX
Net Debt XXX XXX n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

Genmab Stock Performance

As of May 30, 2025, Genmab's stock price is DKK 1379 (or $208).

Genmab has current market cap of DKK 85.0B (or $12.8B), and EV of DKK 64.7B (or $9.7B).

See Genmab trading valuation data

Genmab Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$9.7B $12.8B XXX XXX XXX XXX $16.98

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

Genmab Valuation Multiples

As of May 30, 2025, Genmab has market cap of $12.8B and EV of $9.7B.

Genmab's trades at 21.5x EV/Revenue multiple, and 47.8x EV/EBITDA.

Equity research analysts estimate Genmab's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

Genmab has a P/E ratio of 11.7x.

See valuation multiples for Genmab and 12K+ public comps

Genmab Financial Valuation Multiples

LTM NTM Last FY FY 2025 FY 2026 FY 2027
Market cap (current) $12.8B XXX $12.8B XXX XXX XXX
EV (current) $9.7B XXX $9.7B XXX XXX XXX
EV/Revenue 2.9x XXX 21.5x XXX XXX XXX
EV/EBITDA 8.2x XXX 47.8x XXX XXX XXX
EV/EBIT 9.2x XXX 66.2x XXX XXX XXX
EV/Gross Profit 3.0x XXX n/a XXX XXX XXX
P/E 11.7x XXX 77.6x XXX XXX XXX
EV/FCF 9.0x XXX 62.1x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Genmab Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

Genmab Margins & Growth Rates

Genmab's last 12 month revenue growth is 12%

Genmab's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.1M for the same period.

Genmab's rule of 40 is 48% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Genmab's rule of X is 65% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for Genmab and other 12K+ public comps

Genmab Operational Valuation Multiples

LTM NTM Last FY FY 2025 FY 2026 FY 2027
Revenue Growth 12% XXX 200% XXX XXX XXX
EBITDA Margin 35% XXX 45% XXX XXX XXX
EBITDA Growth 11% XXX 203% XXX XXX XXX
Rule of 40 48% XXX 57% XXX XXX XXX
Bessemer Rule of X XXX XXX 65% XXX XXX XXX
Revenue per Employee XXX XXX $0.2M XXX XXX XXX
Opex per Employee XXX XXX $0.1M XXX XXX XXX
S&M Expenses to Revenue XXX XXX n/a XXX XXX XXX
G&A Expenses to Revenue XXX XXX n/a XXX XXX XXX
R&D Expenses to Revenue XXX XXX 45% XXX XXX XXX
Opex to Revenue XXX XXX 63% XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Genmab Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics and Biopharmaceuticals comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Genmab M&A and Investment Activity

Genmab acquired  XXX companies to date.

Last acquisition by Genmab was  XXXXXXXX, XXXXX XXXXX XXXXXX . Genmab acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Genmab

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Start Free Trial

About Genmab

When was Genmab founded? Genmab was founded in 1998.
Where is Genmab headquartered? Genmab is headquartered in Denmark.
How many employees does Genmab have? As of today, Genmab has 2.7K+ employees.
Who is the CEO of Genmab? Genmab's CEO is Dr. Jan G. J. van de Winkel, PhD.
Is Genmab publicy listed? Yes, Genmab is a public company listed on CSE.
What is the stock symbol of Genmab? Genmab trades under GMAB ticker.
When did Genmab go public? Genmab went public in 2000.
Who are competitors of Genmab? Similar companies to Genmab include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of Genmab? Genmab's current market cap is $12.8B
What is the current revenue of Genmab? Genmab's last 12 months revenue is $22.3B.
What is the current revenue growth of Genmab? Genmab revenue growth (NTM/LTM) is 12%.
What is the current EV/Revenue multiple of Genmab? Current revenue multiple of Genmab is 2.9x.
Is Genmab profitable? Yes, Genmab is EBITDA-positive (as of the last 12 months).
What is the current EBITDA of Genmab? Genmab's last 12 months EBITDA is $7.8B.
What is Genmab's EBITDA margin? Genmab's last 12 months EBITDA margin is 35%.
What is the current EV/EBITDA multiple of Genmab? Current EBITDA multiple of Genmab is 8.2x.
What is the current FCF of Genmab? Genmab's last 12 months FCF is $7.2B.
What is Genmab's FCF margin? Genmab's last 12 months FCF margin is 32%.
What is the current EV/FCF multiple of Genmab? Current FCF multiple of Genmab is 9.0x.

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.